We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Read MoreHide Full Article
Intellia Therapeutics, Inc. (NTLA - Free Report) shares ended the last trading session 23.2% higher at $14.92. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.4% loss over the past four weeks.
The stock rallied after the company reported additional positive data from the phase III HAELO study evaluating lonvo-z for the treatment of hereditary angioedema (HAE). The latest data from the phase III HAELO study showed that treatment with lonvo-z reduced the monthly rate of attacks requiring on-demand by 89% and cut the monthly rate of moderate-to-severe attacks by 91% compared with placebo, the study’s other key secondary endpoints
This company is expected to post quarterly loss of $0.80 per share in its upcoming report, which represents a year-over-year change of +19.2%. Revenues are expected to be $14.51 million, up 1.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Intellia Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NTLA going forward to see if this recent jump can turn into more strength down the road.
Intellia Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Wave Life Sciences (WVE - Free Report) , finished the last trading session 2.2% higher at $6. WVE has returned -13.3% over the past month.
For Wave Life Sciences, the consensus EPS estimate for the upcoming report has changed +3.4% over the past month to -$0.31. This represents no change from what the company reported a year ago. Wave Life Sciences currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Intellia Therapeutics, Inc. (NTLA - Free Report) shares ended the last trading session 23.2% higher at $14.92. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.4% loss over the past four weeks.
The stock rallied after the company reported additional positive data from the phase III HAELO study evaluating lonvo-z for the treatment of hereditary angioedema (HAE). The latest data from the phase III HAELO study showed that treatment with lonvo-z reduced the monthly rate of attacks requiring on-demand by 89% and cut the monthly rate of moderate-to-severe attacks by 91% compared with placebo, the study’s other key secondary endpoints
This company is expected to post quarterly loss of $0.80 per share in its upcoming report, which represents a year-over-year change of +19.2%. Revenues are expected to be $14.51 million, up 1.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Intellia Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NTLA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Intellia Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Wave Life Sciences (WVE - Free Report) , finished the last trading session 2.2% higher at $6. WVE has returned -13.3% over the past month.
For Wave Life Sciences, the consensus EPS estimate for the upcoming report has changed +3.4% over the past month to -$0.31. This represents no change from what the company reported a year ago. Wave Life Sciences currently has a Zacks Rank of #3 (Hold).